Sharkey Howes & Javer Purchases New Shares in Stryker Co. (NYSE:SYK)

Sharkey Howes & Javer purchased a new stake in shares of Stryker Co. (NYSE:SYK) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 710 shares of the medical technology company’s stock, valued at approximately $213,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Freedom Wealth Alliance LLC purchased a new stake in Stryker during the 4th quarter valued at $26,000. Quarry LP purchased a new stake in Stryker during the 1st quarter valued at $27,000. Rise Advisors LLC raised its holdings in Stryker by 692.9% during the 3rd quarter. Rise Advisors LLC now owns 111 shares of the medical technology company’s stock valued at $30,000 after buying an additional 97 shares during the period. West Tower Group LLC purchased a new stake in Stryker during the 2nd quarter valued at $35,000. Finally, Cornerstone Planning Group LLC purchased a new stake in Stryker in the second quarter worth $38,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Canaccord Genuity Group upgraded Stryker from a “hold” rating to a “buy” rating and set a $360.00 target price on the stock in a research note on Wednesday, January 31st. Roth Mkm increased their target price on Stryker from $345.00 to $348.00 and gave the stock a “buy” rating in a research note on Wednesday, January 31st. Royal Bank of Canada reiterated an “outperform” rating and issued a $360.00 target price on shares of Stryker in a research note on Thursday, February 15th. StockNews.com upgraded Stryker from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Finally, Wells Fargo & Company increased their target price on Stryker from $336.00 to $364.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 31st. Three research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $331.52.

Insiders Place Their Bets

In related news, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $341.00, for a total transaction of $1,116,093.00. Following the completion of the sale, the director now owns 14,242 shares of the company’s stock, valued at $4,856,522. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, CAO William E. Berry, Jr. sold 7,690 shares of Stryker stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $358.48, for a total transaction of $2,756,711.20. Following the completion of the transaction, the chief accounting officer now directly owns 3,675 shares in the company, valued at $1,317,414. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 3,273 shares of Stryker stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $341.00, for a total value of $1,116,093.00. Following the transaction, the director now owns 14,242 shares of the company’s stock, valued at $4,856,522. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 212,109 shares of company stock valued at $72,845,768. 5.90% of the stock is currently owned by corporate insiders.

Stryker Stock Down 0.2 %

SYK stock traded down $0.84 during trading on Friday, reaching $357.87. 1,074,753 shares of the company traded hands, compared to its average volume of 1,130,776. Stryker Co. has a 12 month low of $249.98 and a 12 month high of $361.41. The business has a 50 day simple moving average of $344.28 and a 200 day simple moving average of $305.97. The company has a market capitalization of $136.16 billion, a price-to-earnings ratio of 43.38, a price-to-earnings-growth ratio of 2.92 and a beta of 0.89. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.97 and a current ratio of 1.58.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $3.46 earnings per share for the quarter, beating analysts’ consensus estimates of $3.27 by $0.19. The company had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Stryker had a return on equity of 22.99% and a net margin of 15.44%. The firm’s revenue for the quarter was up 11.8% compared to the same quarter last year. During the same quarter last year, the company earned $3.00 earnings per share. On average, equities research analysts anticipate that Stryker Co. will post 11.86 earnings per share for the current fiscal year.

Stryker Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, April 30th. Shareholders of record on Friday, March 29th will be issued a $0.80 dividend. This represents a $3.20 annualized dividend and a yield of 0.89%. The ex-dividend date of this dividend is Wednesday, March 27th. Stryker’s dividend payout ratio is presently 38.79%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.